Volumetric modulated arc therapy for thoracic node metastases: A safe and effective treatment for a neglected disease

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To evaluate the outcome of Stereotactic Body Radiation Therapy (SBRT) with Volumetric Modulated Arc Therapy (VMAT) for thoracic node metastases. Results: 18 out of 29 patients presented with isolated thoracic node metastases with no other sites of disease. Median prescribed dose was 45Gy (range 30-60Gy). Acute toxicity was recorded as G0 in 28 patients, while one patient was scored as G1. Late toxicity was G0 in 26 patients, one patient was scored G1, one as G2, and one as G4 presented acute myocardial infarction. During follow up, the best local response was complete remission in 14 patients and partial remission in 11 patients. With a median follow up of 12 months (range 2-35) 9 patients died from disease progression, 10 were still alive with distant metastases, 5 had a locally controlled disease and 5 patients were disease free. The median OS estimated was 18 months (76%, 49% at one, two years). The median PFS was 9 months (28%, 17% at one, two years). Metrials and Methods: Twenty-nine patients with 32 thoracic nodes metastases were treated with SBRT in our institution. Toxicities and response were assessed. Overall Survival (OS) and Progression Free Survival (PFS) were evaluated. Conclusions: SBRT is an efficient treatment for thoracic node metastases.

Original languageEnglish
Pages (from-to)53321-53329
Number of pages9
JournalOncotarget
Volume7
Issue number33
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Neglected Diseases
Intensity-Modulated Radiotherapy
Thorax
Neoplasm Metastasis
Therapeutics
Radiotherapy
Disease-Free Survival
Survival
Disease Progression
Myocardial Infarction

Keywords

  • Mediastinal nodes
  • Oligometastases
  • SBRT

ASJC Scopus subject areas

  • Oncology

Cite this

@article{72cd2ab9ab25458e83b67002d5e2b9da,
title = "Volumetric modulated arc therapy for thoracic node metastases: A safe and effective treatment for a neglected disease",
abstract = "Purpose: To evaluate the outcome of Stereotactic Body Radiation Therapy (SBRT) with Volumetric Modulated Arc Therapy (VMAT) for thoracic node metastases. Results: 18 out of 29 patients presented with isolated thoracic node metastases with no other sites of disease. Median prescribed dose was 45Gy (range 30-60Gy). Acute toxicity was recorded as G0 in 28 patients, while one patient was scored as G1. Late toxicity was G0 in 26 patients, one patient was scored G1, one as G2, and one as G4 presented acute myocardial infarction. During follow up, the best local response was complete remission in 14 patients and partial remission in 11 patients. With a median follow up of 12 months (range 2-35) 9 patients died from disease progression, 10 were still alive with distant metastases, 5 had a locally controlled disease and 5 patients were disease free. The median OS estimated was 18 months (76{\%}, 49{\%} at one, two years). The median PFS was 9 months (28{\%}, 17{\%} at one, two years). Metrials and Methods: Twenty-nine patients with 32 thoracic nodes metastases were treated with SBRT in our institution. Toxicities and response were assessed. Overall Survival (OS) and Progression Free Survival (PFS) were evaluated. Conclusions: SBRT is an efficient treatment for thoracic node metastases.",
keywords = "Mediastinal nodes, Oligometastases, SBRT",
author = "Davide Franceschini and {De Rose}, Fiorenza and Antonella Fogliata and Piera Navarria and Ascolese, {Anna Maria} and Ciro Franzese and Tiziana Comito and Angelo Tozzi and Cristina Iftode and {Di Brina}, Lucia and Giuseppe D'Agostino and Elena Clerici and Luca Cozzi and Marta Scorsetti",
year = "2016",
month = "8",
day = "1",
doi = "10.18632/oncotarget.10826",
language = "English",
volume = "7",
pages = "53321--53329",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "33",

}

TY - JOUR

T1 - Volumetric modulated arc therapy for thoracic node metastases

T2 - A safe and effective treatment for a neglected disease

AU - Franceschini, Davide

AU - De Rose, Fiorenza

AU - Fogliata, Antonella

AU - Navarria, Piera

AU - Ascolese, Anna Maria

AU - Franzese, Ciro

AU - Comito, Tiziana

AU - Tozzi, Angelo

AU - Iftode, Cristina

AU - Di Brina, Lucia

AU - D'Agostino, Giuseppe

AU - Clerici, Elena

AU - Cozzi, Luca

AU - Scorsetti, Marta

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose: To evaluate the outcome of Stereotactic Body Radiation Therapy (SBRT) with Volumetric Modulated Arc Therapy (VMAT) for thoracic node metastases. Results: 18 out of 29 patients presented with isolated thoracic node metastases with no other sites of disease. Median prescribed dose was 45Gy (range 30-60Gy). Acute toxicity was recorded as G0 in 28 patients, while one patient was scored as G1. Late toxicity was G0 in 26 patients, one patient was scored G1, one as G2, and one as G4 presented acute myocardial infarction. During follow up, the best local response was complete remission in 14 patients and partial remission in 11 patients. With a median follow up of 12 months (range 2-35) 9 patients died from disease progression, 10 were still alive with distant metastases, 5 had a locally controlled disease and 5 patients were disease free. The median OS estimated was 18 months (76%, 49% at one, two years). The median PFS was 9 months (28%, 17% at one, two years). Metrials and Methods: Twenty-nine patients with 32 thoracic nodes metastases were treated with SBRT in our institution. Toxicities and response were assessed. Overall Survival (OS) and Progression Free Survival (PFS) were evaluated. Conclusions: SBRT is an efficient treatment for thoracic node metastases.

AB - Purpose: To evaluate the outcome of Stereotactic Body Radiation Therapy (SBRT) with Volumetric Modulated Arc Therapy (VMAT) for thoracic node metastases. Results: 18 out of 29 patients presented with isolated thoracic node metastases with no other sites of disease. Median prescribed dose was 45Gy (range 30-60Gy). Acute toxicity was recorded as G0 in 28 patients, while one patient was scored as G1. Late toxicity was G0 in 26 patients, one patient was scored G1, one as G2, and one as G4 presented acute myocardial infarction. During follow up, the best local response was complete remission in 14 patients and partial remission in 11 patients. With a median follow up of 12 months (range 2-35) 9 patients died from disease progression, 10 were still alive with distant metastases, 5 had a locally controlled disease and 5 patients were disease free. The median OS estimated was 18 months (76%, 49% at one, two years). The median PFS was 9 months (28%, 17% at one, two years). Metrials and Methods: Twenty-nine patients with 32 thoracic nodes metastases were treated with SBRT in our institution. Toxicities and response were assessed. Overall Survival (OS) and Progression Free Survival (PFS) were evaluated. Conclusions: SBRT is an efficient treatment for thoracic node metastases.

KW - Mediastinal nodes

KW - Oligometastases

KW - SBRT

UR - http://www.scopus.com/inward/record.url?scp=84982298179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982298179&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10826

DO - 10.18632/oncotarget.10826

M3 - Article

AN - SCOPUS:84982298179

VL - 7

SP - 53321

EP - 53329

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 33

ER -